Cantor Fitzgerald Begins Coverage on Aquestive Therapeutics

On Tuesday, analysts from Cantor Fitzgerald announced that they are now covering shares of Aquestive Therapeutics (NASDAQ:AQST). In their report, they assigned an "overweight" rating to the company’s stock, along with a price target of $17.00. This target suggests a significant potential upside of approximately 372.22% from where the stock closed previously.

Recent analyses by other firms have also shed light on Aquestive Therapeutics. For instance, on October 25th, Leerink Partners raised their price target for the stock from $12.00 to $13.00 while assigning an "outperform" rating. Similarly, HC Wainwright reiterated a "buy" rating with a target price of $10.00 in another research note on November 6th. Furthermore, JMP Securities maintained a "market outperform" rating, setting a price objective of $9.00 as of October 8th. In total, six analysts have given the stock a buy rating, with one indicating a strong buy. Current consensus ratings provide a "Buy" designation for the company, with an average target price of around $11.00.

Aquestive Therapeutics Stock Performance

On Tuesday, shares of Aquestive Therapeutics opened at $3.60. Over the past year, the stock has reached a low of $1.84 and a high of $6.23. Currently, the company has a market capitalization of $328.24 million, with a 50-day moving average price of $4.83 and a 200-day moving average price of $4.06. The stock has a price-to-earnings ratio of -8.00 and a beta of 2.62, indicating higher volatility compared to the market.

Recent Earnings Data

Aquestive Therapeutics recently shared its quarterly earnings on November 4th, reporting a loss of $0.13 per share. This result fell short of analysts' expectations, which had estimated a loss of $0.12 per share. The company's revenue for the quarter totaled $13.54 million, exceeding the forecast of $12.69 million. In the same quarter last year, the company's loss per share was $0.03. Analysts anticipate a projected earnings per share (EPS) of -0.47 for the upcoming fiscal year.

Institutional Ownership Trends

A number of institutional investors have made changes to their holdings in Aquestive Therapeutics recently. For example, State Street Corp increased its stake by 52.1% in the third quarter, acquiring an additional 512,682 shares to bring their total to 1,496,739 shares. Additionally, Blue Owl Capital Holdings LP raised its position by 30.3%, adding 265,000 shares in the second quarter, which brought their total to 1,140,000 shares. Other firms, including the Bank of New York Mellon Corp and Verition Fund Management LLC, have also made new investments in the company this quarter. Overall, institutional investors currently hold about 32.45% of Aquestive Therapeutics’ stock.

Aquestive Therapeutics Company Overview

Aquestive Therapeutics Inc is a pharmaceutical company that operates both in the United States and internationally. The company is known for its products like Sympazan, an oral soluble film formulation containing clobazam, targeted for treating Lennox-Gastaut syndrome; Suboxone, which is a sublingual film formulation for opioid dependence; Zuplenz, an oral film designed to address nausea and vomiting related to chemotherapy and post-surgery; and Azstarys, intended for the management of attention deficit hyperactivity disorder.

stock, analysis, performance